Literature DB >> 6171694

Patient with circulating antibodies to alpha-interferon.

K E Mogensen, P Daubas, I Gresser, D Sereni, B Varet.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6171694     DOI： 10.1016/s0140-6736(81)91460-4

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  10 in total

1.  Neutralizing antibodies to granulocyte-macrophage colony-stimulating factor, interleukin-1alpha and interferon-alpha but not other cytokines in human immunoglobulin preparations.

Authors:  M Wadhwa; A Meager; P Dilger; C Bird; C Dolman; R G Das; R Thorpe
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

2.  Autoantibodies to crude human leucocyte interferon (IFN), native human IFN, recombinant human IFN-alpha 2b and human IFN-gamma in healthy blood donors.

Authors:  C Ross; M B Hansen; T Schyberg; K Berg
Journal:  Clin Exp Immunol       Date:  1990-10       Impact factor: 4.330

3.  Low incidence of antibody formation due to long-term interferon-alpha 2c treatment of cancer patients.

Authors:  G G Steinmann; B Göd; F Rosenkaimer; G Adolf; G Bidlingmaier; B Frühbeis; H Lamche; J Lindner; E Patzelt; C Schmähling
Journal:  Clin Investig       Date:  1992-02

4.  Clinical effect of interferon in malignant brain tumours.

Authors:  M Nagai; T Arai
Journal:  Neurosurg Rev       Date:  1984       Impact factor: 3.042

5.  Binding of cytokines to pharmaceutically prepared human immunoglobulin.

Authors:  M Svenson; M B Hansen; K Bendtzen
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

6.  Assessment of the antigenic response in humans to a recombinant mutant interferon beta.

Authors:  M W Konrad; A L Childs; T C Merigan; E C Borden
Journal:  J Clin Immunol       Date:  1987-09       Impact factor: 8.317

7.  Spontaneous interferon-alpha antibodies in a patient with pure red cell aplasia and recurrent cutaneous carcinomas.

Authors:  O Prümmer; N Frickhofen; W Digel; H Heimpel; F Porzsolt
Journal:  Ann Hematol       Date:  1991 Feb-Mar       Impact factor: 3.673

8.  High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG.

Authors:  C Ross; M Svenson; M B Hansen; G L Vejlsgaard; K Bendtzen
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

9.  Natural human antibodies to gamma interferon interfere with the immunomodulating activity of the lymphokine.

Authors:  A Turano; A Balsari; E Viani; S Landolfo; L Zanoni; F Gargiulo; A Caruso
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

Review 10.  Recent Issues in Varicella-Zoster Virus Latency.

Authors:  Peter G E Kennedy; Trine H Mogensen; Randall J Cohrs
Journal:  Viruses       Date:  2021-10-07       Impact factor: 5.048
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.